2024 Chinese Expert Consensus Guidelines on the Diagnosis and Treatment of Atrial Fibrillation in the Elderly, Endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular branch): Executive Summary

Abstract

The consensus guidelines of the Geriatric Society of Chinese Medical Association on the management of atrial fibrillation (AF) in the elderly was first published in 2011 and updated in 2016, with endorsement by Chinese Society of Geriatric Health Medicine. Since then, many important studies regarding the screening and treatment in the elderly population have been reported, necessitating this updated expert consensus guideline. The writing committee members comprehensively reviewed updated evidence pertaining to elderly patients with AF, and formulated this 2024 update. The highlighted issues focused on the following: screening for AF, geriatric comprehensive assessment, use of the Atrial fibrillation Better Care (ABC) pathway for the elderly patients, and special clinical settings related to elderly patients with AF. New recommendations addressing smart technology facilitated AF screening, ABC pathway based management, and optimal anticoagulation were developed, with a focus on the elderly.

Keywords

atrial fibrillation - elderly - management - consensus guideline - executive summary

Introduction

The consensus guidelines of the Geriatric Society of Chinese Medical Association on the management of atrial fibrillation (AF) in the elderly was first published in 2011 and updated in 2016,[1] [2] with endorsement by Chinese Society of Geriatric Health Medicine. Since then, many important studies regarding the screening and treatment in the elderly population have been reported, necessitating this updated expert consensus guidelines.

This is an executive summary of the full consensus guideline, which is published in Chinese Journal of Cardiac Arrhythmias.[3] The writing committee members comprehensively reviewed updated evidence pertaining to elderly patients with AF, and formulated this 2024 update. The highlighted issues focused on the following: screening for AF, geriatric comprehensive assessment, use of the Atrial fibrillation Better Care (ABC) pathway for the elderly patients, and special clinical settings related to elderly patients with AF. New recommendations addressing smart technology-facilitated AF screening, ABC pathway-based management, and optimal anticoagulation were developed, with a focus on the elderly.

Epidemiology of the Elderly AF Population

AF prevalence increases with increasing age, being 0.72% in the population aged 55 to 59 years, 6.52% in aged 80 to 84 years, and 8.18% in aged over 95 years.[4] The increasing aging population and chronic diseases increases the risk of AF and AF-related stroke in the elderly population in China. The lifetime risk of AF of the population aged over 75 years is doubled compared to those aged 50 years.[5] Thus it is estimated that there are currently 20 million adult AF patients in China.[6] [7] In the 2018 Blue Book on the Prevention and Treatment of Atrial Fibrillation in China, the elderly population with AF was modelled to exceed 9 million by the year 2050.[4]

The elderly AF population often have a variety of diseases, such as coronary heart disease (CAD), arteriosclerosis, heart failure (HF), valvular disease, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, chronic anemia, chronic kidney disease, tumor, etc. Indeed, the optimal thromboprophylaxis in the Chinese elderly Patients with atrial Fibrillation (ChiOTEAF) registry found that 73.2% of the elderly AF population aged over 75 years had ≥2 comorbidities and 35.7% were treated with over five or more drugs.[8] Such clinically complex phenotypes of AF patients with multimorbidity, frailty, and polypharmacy have important implications for treatment and prognosis.[9] [10] [11]

These comorbidities were independently associated with thromboembolic and bleeding risks, which results in poor adherence to anticoagulation amongst elderly patients with AF.[12] Some evidence suggests that Asian patients are more sensitive to anticoagulation, in terms of bleeding,[13] [14] but ethnic differences in thromboembolism and intracranial bleeding are evident.[15] [16]

Recommendations

• Aging and chronic disease increase the risk of AF and stroke in the elderly population.

• The elderly population with AF often have multiple comorbidities, contributing to clinically complex phenotypes, with implications for AF-related complications, such as thromboembolism.

• A geriatric general assessment and proactive management of comorbidities are needed in these elderly patients ([Fig. 1]).

Fig. 1 Risk assessment of the elderly patients with AF. For the patients with a CHA₂DS₂-VASc score of low or intermediate risk at baseline, more frequent stroke risk evaluation, e.g., every 4 months, is proposed. AF, atrial fibrillation; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; CAD, coronary artery disease; CHA₂DS₂-VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, age 65–74 years, sex category (female); CKD-EP, Chronic Kidney Disease Epidemiology Collaboration; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; HF, heart failure; INR, international normalized ratio; LV, left ventricular; LVEF, left ventricular ejection fraction; NSAID, nonsteroidal anti-inflammatory drug; PAD, peripheral artery disease; SBP, systolic blood pressure; TIA, transient ischemic attack; TTR, time in therapeutic range; VKA, vitamin K antagonist.

Atrial Fibrillation Stages

AF is a progressive disease, contributed by an unhealthy lifestyle and risk factors over an individual patient's lifetime.[17] AF stages, defined as those at risk for AF, pre-AF, AF, and permanent AF, emphasizes prevention through addressing modifiable risk factors and the appropriate treatments based on AF burden.[18]

The population at risk for AF includes susceptible factors to AF, such as obesity, obstructive sleep apnea (OSA), physical inactivity, alcohol, diabetes, hypertension, and other nonmodifiable risk factors.[19] At pre-AF stage, there is the evidence of structural or electrical changes further predisposing to AF, such as atrial enlargement, frequent atrial ectopy, short bursts of atrial tachycardia, with HF, valve disease, CAD, hypertrophic cardiomyopathy, thyroid disease, etc. At the AF stage, AF burden can be continuously monitored to track the progression of disease. At the permanent AF stage, rhythm control approaches are discontinued.

Recommendations

• AF stages can be classified into at risk for AF, pre-AF, AF, and permanent AF.

• Holistic risk factor management is recommended to reduce naive or recurrent onset of AF at the earlier stages.

• Appropriate stroke prevention and individualized patient-centered symptom-directed rate or rhythm management should be administered, as appropriate.

AF Screening

Screening techniques for AF include photoplethysmography (PPG), single/multi-lead electrocardiogram (ECG), accelerometer, etc. There are a variety of screening devices, such as handheld devices, wristbands/watches, chest straps, and stickers. The common screening strategies are as follows: general population screening and “targeted” population screening, intermittent testing/continuous monitoring, consumer-led screening, or physician/nurse-led screening. The detected rate of targeted screening is higher than that of general population screening.

The more frequent and longer the AF monitoring, the higher the sensitivity of AF detection.[20] Compared with intermittent testing of single-lead ECG, PPG-based wearables demonstrated the good detection of AF,[21] with the advantage of the continuous monitoring and low cost. Moreover, the wearables can detect the susceptible factors to AF (e.g., OSA, hypertension).[22] With the use of validated wearables, a consumer-led screening approach can be applied for the detection of AF[23] and its susceptible risk factors.[24]

Screening for AF with validated wearables in the elderly,[25] or the high-risk population, such as with OSA, hypertension, diabetes, and post-stroke, will facilitate the early detection and management of AF.

Recommendation

• With the updated evidence on the application of wearable device technology, the use of smart devices, with PPG or single/multiple-lead ECG, for AF screening is recommended in the elderly population, or in high-risk populations, e.g., those with OSA, hypertension, diabetes, post-stroke, etc. ([Fig. 2]).

Fig. 2 AF screening and monitoring for the elderly population. AF, atrial fibrillation; OSA, obstructive sleep apnea.

Holistic or Integrated Care Management for the Elderly

A holistic or integrated care approach, with the well-validated ABC pathway is recommended for the elderly population with AF to improve clinical outcomes ([Fig. 3]).

• “A”: Avoid stroke with anticoagulation using non-vitamin K antagonist oral anticoagulants (NOACs) or well-managed warfarin (international normalized ratio [INR] 2.0–3.0 with time in therapeutic range [TTR] ≥70%) in patients at high risk of stroke. An INR of 1.6 to 2.5 may be considered in frail elderly patients aged over 75 years or HAS-BLED score ≥3, as lower INR targets appear to reduce bleeding but increases thromboembolism in AF.[26] Good-quality anticoagulation control with TTR ≥70% is associated with low thromboembolism and bleeding risks.

Fig. 3 An integrated care ABC pathway for the elderly population with atrial fibrillation. COPD, chronic obstructive pulmonary disease; F, female; m, male; INR, international normalized ratio; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; OSA, obstructive sleep apnea.

In patients at intermediate risk for stroke (i.e., stroke prevalence of 1–2%/year, i.e., CHA₂DS₂-VASc = 1 in male or = 2 in female) could benefit from the modification of risk factors. No antithrombotic therapy is recommended in low-risk subjects, i.e., CHA₂DS₂-VASc = 0 in male or = 1 in female, but elderly AF patients would not be in this category, being at age ≥65 years.

For the patients with intermediate- or high-risk stroke, but with long-term oral anticoagulant contraindications due to irreversible causes, percutaneous left atrial appendage closure is recommended.

In patients with high risk for AF, e.g., left atrial enlargement, COPD, HF, stroke prevalence of >2%/year, it is recommended to monitor for AF occurrences and consideration of oral anticoagulation.

In a systematic review, patients with atrial high-rate episode (AHRE) detected by cardiac-implantable electronic devices (CIEDs), the risk ratio (RR) for thromboembolic events in AHRE patients was 2.13 (95% confidence interval [CI]: 1.53–2.95, I²: 0%), while the RR for incident clinical AF was 3.34 (95% CI: 1.89–5.90, I²: 73%).[27] In other studies, AHRE ≥24 hours developed more ECG-diagnosed AF (17.0%/patient-year) than patients with shorter AHRE (8.2%/patient-year, detected by implanted cardiac device in recent trials).[28] [29]

In a real-world cohort of CIED patients with median follow-up of 24.3 (10.6–40.3) months, 29.8% patients experienced the composite outcome of clinical AF or AHRE episodes lasting ≥24 hours.[30] Baseline CHA₂DS₂-VASc score and the longest AHRE episode at enrollment lasting 12 to 23 hours 59 minutes were independently associated with the composite outcome (hazard ratio [HR]: 1.40, 95% confidential interval [CI]: 1.07–1.83 and HR: 8.15, 95% CI: 2.32–28.65, respectively).[30] Thus, baseline patients' characteristics (CHA₂DS₂-VASc score) and AHRE duration may help to intensify monitoring and decision-making, being independently associated with clinical AF at follow-up.

Two randomized trials, the NOAH-AFNET 6 and ARTESiA trials, provide high-quality evidence on the anticoagulation for patients with device-detected AF.[28] [31] Among patients with subclinical AF, with at least one episode lasting 6 minutes or longer but no episodes lasting longer than 24 hours, detected by implanted cardiac device, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but this was with a higher risk of major bleeding.[31] For the patients with AHRE also detected with implanted cardiac device in the NOAH-AF trial, anticoagulation with edoxaban did not significantly reduce the incidence of a composite of cardiovascular death, stroke, or systemic embolism as compared with placebo in NOAH-AFNET 6.[28] [29] Meta-analysis of NOAH-AFNET 6 and ARTESiA trials demonstrated that oral anticoagulation reduced the risk of stroke in patients with device-detected AF and increased the risk of major bleeding.[32] Taking into account these results, dynamic monitoring of AHRE/AF progression and CHA₂DS₂-VASc, considering the benefits and related risks of oral anticoagulants, and individualized decision making of stroke prevention approach, is proposed for patients with CIED and AHRE.

• “B”: Better patient-centered symptom-directed rate or rhythm control strategies are recommended to reduce AF burden, as well as improve clinical outcomes with early rhythm control for selected patients.

• “C”: Cardiovascular risk and comorbidity management (OSA, diabetes, hypertension, HF, CAD, COPD, pulmonary hypertension, etc.) as well as lifestyle changes (obesity reduction, regular exercise, reducing alcohol/stimulants, psychological morbidity, etc.).

Digital health technology can be used to facilitate AF care pathways.[33] In the mAFA-II randomized trial, smart technology facilitated ABC pathway (mobile Atrial Fibrillation, mAFA) reduced clinical adverse in the elderly patients with AF, reducing the composite endpoints of all-cause death, thromboembolism, and rehospitalization in the elderly patients aged over 75 years, or HF, diabetes, prior thromboembolism, or with multiple morbidity ([Fig. 4]).[34] [35] [36] [37] [38] In a systematic review and meta-analysis, adherence to the ABC pathway was associated with a reduction in mortality, stroke, and bleeding.[39] The potential cost-effective use of streamlining and integrating care via the ABC pathway for AF has been reported.[40] The substantial health care burden associated with AF, from strokes, bleeds, and mortality over the next decades, can be reduced if patients are managed with a holistic or integrated care approach based on the ABC pathway, equating to substantial health care cost reductions.[41]

Fig. 4 Mobile health technology facilitated integrated care for the elderly patients with AF.

Recommendation

• The ABC pathway is recommended for the elderly population with AF.

• Validated smart technology-facilitated ABC pathway management, e.g., mAFA, is a cost-effective tool for the elderly AF population to reduce all-cause death, thromboembolism, and other clinical adverse events.

Risk Assessment for the Elderly Patients

The risk assessment for the elderly AF patients includes assessment of stroke risk, bleeding risk, and comprehensive geriatric assessment.

In our 2016 consensus document, we recommended the use of the CHA₂DS₂-VASc score for stroke risk assessment for the elderly AF patients. In this 2024 update, we still recommend the use of the CHA₂DS₂-VASc score as the most validated stroke risk prediction scheme. The assessment of dynamic changes on stroke risk with re-evaluation of the CHA₂DS₂-VASc score is recommended at least annually.[42] For the patients with a CHA₂DS₂-VASc score of low or intermediate risk at baseline, more frequent stroke risk evaluation,[43] e.g., every 4 months, is proposed.

The HAS-BLED score is recommended for the bleeding risk for the elderly patients with AF, with the advantage of simplicity, as well as a better predictive ability of hemorrhage and major bleeding (including intracranial bleeding).[44] The HAS-BLED score has been extensively validated in patients without anticoagulant, with oral anticoagulants, and NOAC.[45] [46] [47] With the initiation of anticoagulant, regular bleeding risk assessment with the HAS-BLED score helps to mitigate modifiable bleeding risk factors, schedule high bleeding risk patients for early review and follow-up, and to improve oral anticoagulant uptake.[48]

The comprehensive geriatric assessment, including disability assessment (ADL scale),[49] frailty screening (FRAIL scale),[50] gait abnormality and fall risk assessment (TUGT scale),[51] fall scale screening, cognitive function assessment (Mini-Cog scale),[52] renal function [eGFR, CKD-EPI (Scr/Cys-c) formula], nutritional status, diet and weight, depressive status, comorbidities, and combined with multiple drugs, is recommended.

Recommendation

• The CHA₂DS₂-VASc score for stroke risk and HAS-BLED for bleeding risk are recommended for risk stratification in elderly AF patients.

• The Comprehensive Geriatric Assessment should be performed to improve the adherence to the anticoagulant.

Rhythm/Rate Control with Drugs

The purpose of rhythm or rate control for the elderly patients with AF is to relieve the symptoms, reduce the frequency and duration of AF episodes, maintain cardiac function, prevent from the tachycardia cardiomyopathy, improve quality of life, and reduce the hospitalization.

The antiarrhythmic drugs for cardioversion include Class I c (propafenone) and Class III (amiodarone, ibutilide). Amiodarone can effectively convert AF to sinus rhythm, with the successful rate of 35 to 90% during 8 to 24 hours. However, the concurrent use of amiodarone and NOACs might increase the risk of major bleeding among older patients.[53] [54] Ibutilide is an effective drug for conversion of recent-onset AF and flutter in elderly patients, with the overall rate of successful conversion was 59%.[55] There is up to a 4% risk of torsade de pointes and a 4.9% risk of monomorphic ventricular tachycardia, especially for the elderly patients, female, low weight, or with HF. In addition, propafenone can increase the blood concentration of warfarin and digoxin. Hence, close monitoring is warranted during and after drug infusion for the elderly patients receiving cardioversion.

Intravenous sotalol is less effective than ibutilide in AF, with the underlyingly increased risk of mortality for maintaining sinus rhythm.[56] Dronedarone was less sufficient than amiodarone in converting AF. Therefore, we do not recommend the use of sotalol and dronedarone for the cardioversion in elderly patients with AF.

Recommendation

• A patient-centered symptom-directed rhythm or rate control approach is recommended for the elderly population with AF.

Rhythm/Rate Control with Invasive Procedures

Cardioversion

Early rhythm-control therapy was associated with a lower risk of adverse cardiovascular outcomes than usual care among elderly patients with early AF and cardiovascular conditions.[57] [58] For elderly patients with AF diagnosed ≤12 months, or the uncontrolled ventricular rate, or severe symptom with controlled ventricular rate, or patients willing to restore sinus rhythm, cardioversion is recommended. However, in patients with left atrial thrombosis or sick sinus syndrome without pacemaker, atrioventricular block and QT interval correction prolongation (>500 ms) are contraindications to cardioversion.

Electrocardioversion can be used as an effective means of emergency management for patients with AF with obvious hemodynamic disturbance, myocardial ischemia, or pre-excitation syndrome with rapid ventricular rate, and can also be used for selective cardioversion treatment for patients with persistent and long-duration persistent AF. Electrocardioversion may lead to complications in the elderly population, including sedation-related complications, cardiac arrest, skin burn, etc., and there is a risk of inducing pulmonary edema in patients with left ventricular dysfunction or HF.

Oral anticoagulant during peri-procedure significantly reduces the risk of thromboembolism. In patients with AF of ≥48 hours or unknown duration, warfarin (INR 2.0–3.0 or 1.6–2.5 for those aged ≥75 years) or NOAC therapy should be used for at least 3 weeks prior to cardioversion. For those with AF <48 hours, cardioversion may be performed with heparin, low-molecular-weight heparin, or NOAC during the peri-procedure. Anticoagulation therapy is required for 4 weeks after cardioversion, regardless of the duration of pre-cardioversion. After 4 weeks, long-term anticoagulation therapy can be determined based on the stroke risk.

Those who need early cardioversion should be performed after transesophageal ultrasound to rule out intra-atrial thrombus. In patients with hemodynamic instability, cardioversion should be initiated immediately while anticoagulant therapy is initiated with heparin or low-molecular-weight heparin.

Pacemakers

The elderly AF patient with bradyarrhythmias can be a candidate for pacemaker therapy. For elderly patients with AF and HF, cardiac resynchronization therapy improves left ventricle ejection fraction, quality of life, and all-cause mortality.

Catheter Ablation

Left atrial enlargement and fibrosis increased with aging. AF ablation-related complications showed the increased trend over aging, such as cardiovascular adverse events, death, AF recurrence, postoperative atrial flutter, etc. Therefore, catheter ablation in elderly patients needs to fully weight the benefits and risks. Catheter ablation should not be proposed for the patients with contraindications to anticoagulant therapy.

Appropriate measures should be taken to reduce AF recurrence after the ablation for the elderly patients ([Fig. 5]). The decision on long-term anticoagulation after ablation depends on the individual's risk profile.

Fig. 5 Appropriate measures to reduce AF recurrence for the elderly patients receiving ablation. Clinical recurrence of AF: late recurrence or very late recurrence. AF, atrial fibrillation.

Recommendation

• The risk and benefits should be weighted for the elderly patients receiving invasive rhythm or rate control.

• Long-term anticoagulation should be considered for patients at high-risk stroke.

Antithrombotic Treatment

The elderly patients with AF are often clinically complex, with the cardiac, venous, and arterial thromboembolic risks. The ChiOTEAF demonstrated that elderly patients with AF were often at risk of falls, with associated atherosclerosis, chronic kidney disease/liver disease, or malignancy, increasing the risks of thrombosis and bleeding ([Fig. 6]).[59]

Fig. 6 Risk reductions in elderly patients with AF on OACs in special clinical setting (very elderly, multimorbidities, with CAD) and the increased risk of those without OACs or with underdosing of OACs. *TE and all-cause death reduced among the very elderly patients and with multimorbidities on OACs. The composite of all-cause death, TE, major bleeding, and acute coronary syndrome was reduced in the elderly patients with OACs. **For elderly patients with AF without OACs, the thromboembolic risk increased by 2.2-fold in those with CHA2DS2-VASc ≥1 in male, or ≥2 in female and by 2.5-fold in those with the underdoing of OACs. CAD, coronary artery disease; OACs, oral anticoagulants; TE, thromboembolism. (Cited from Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. Eur Heart J Qual Care Clin Outcomes. 2023 J Arrhythm. 2022; Int J Stroke. 2022; Int J Stroke. 2021.[12] [59] [60] [61])

Nonetheless, oral anticoagulation therapy for high-risk elderly AF patients, even with fall risk, HF, chronic kidney disease/liver disease, and malignant tumor, is associated with a reduction in the composite end points of acute myocardial infarction, ischemic stroke, cerebral hemorrhage, and all-cause death ([Fig. 6]).[60] In elderly patients aged over 85 years of age, optimized oral anticoagulant therapy decreased the composite end point of thrombosis and all-cause death by 54% without increasing the risk of major bleeding events (OR 0.46; 95% CI: 0.32–0.66; p < 0.001).[34]

However, less than half of elderly Chinese patients with AF at high risk for stroke receive oral anticoagulation.[59] In the ChiOTEAF registry, for example, only 26.4% received oral anticoagulation therapy in Chinese elderly patients aged over 85 years.[60] Chronic kidney disease, liver disease, dementia, and prior bleeding were independent risk factors for the poor adherence to oral anticoagulant therapy. Such poor adherence to the anticoagulant therapy increased the risk of thromboembolism and all-cause death by two- and fourfold, respectively ([Fig. 6]).[61]

A meta-analysis of 22 studies confirmed that NOACs, compared to warfarin, reduced the risk of stroke and systemic embolism, intracranial bleeding, hemorrhagic stroke, and fatal bleeding in the elderly patients aged over 75 years.[62] Even for the extremely high-risk, very elderly (>90 years) patients, NOACs were associated with a lower risk of composite endpoint of ischemic stroke, intracranial hemorrhage, major bleeding, or mortality compared to warfarin or nonoral anticoagulants.[63] However, the bleeding risk associated with anticoagulant still needs to be monitored with proactive management, especially gastrointestinal bleeding among elderly patients.[62]

Moreover, inadequate off-label underdosing of oral anticoagulants is common in elderly patients with AF. In China, for example, one in five elderly aged over 75 years received inadequate dosage of oral anticoagulant (warfarin or NOAC), with a higher risk of the composite outcome and thromboembolic events compared with standard-dose NOAC.[61]

In AF patients over 80 years in high-risk elderly AF patients at increased bleeding risk, use of very low dosage (edoxaban 15 mg o.d., dabigatran 110 or 150 o.d., apixaban 2.5 mg o.d., or rivaroxaban 10 mg) was associated with a greater risk of arterial (major adverse limb events requiring lower limb revascularization or amputation, HR: 1.54, 95% CI: 1.09–2.18; p = 0.014) and venous thromboses (HR: 3.75, 95% CI: 1.56–8.97; p = 0.003), and death (HR: 1.21, 95% CI: 1.15–1.29; p < 0.001), when compared with those of regular-dosage NOAC.[64]

Adherence to the ABC pathway was associated with a lower composite outcome of all-cause death and any thromboembolic event (stroke, transient ischemic attack, peripheral embolism) even amongst the elderly patients with AF.[65]

Recommendation

• Elderly patients, especially high-risk patients, would benefit from the optimal label or guideline-recommended oral anticoagulant after balancing bleeding risk, with a preference for NOACs. More intensive follow-up, e.g., risk factor monitoring, the intensity and safety of anticoagulant, liver/renal function, etc. should be taken to improve poor adherence to oral anticoagulant. Cognitive function should be assessed, and patient's education should be encouraged to avoid missing doses or noncompliance.

• NOACs are preferred for the elderly patients with AF than warfarin, except those with mechanical valve or severe mitral stenosis. If on warfarin, INR should remain between 2.0 and 3.0 or 1.6 and 2.5 for those aged over 75 years. Good quality anticoagulation control (TTR ≥ 65%) should be aimed for.

• Minor bleeding associated with NOAC can be managed conservatively and if necessary, the NOAC could be discontinued for 12 to 24 hours. Moderate bleeding requires blood products, etc., depending on the type of oral anticoagulant. The specific antagonists (vitamin K, idarucizumab, or andexanetα, etc.) can be used for the life-threatening bleeding. Whether or when to resume anticoagulant therapy after bleeding events should be weighted, balancing the risk of thrombosis and bleeding.

Elderly Patients with CAD

PIONEER-AF,[66] REDUAL,[67] AUGUSTUS,[68] and ENTRUST[69] trials confirmed that the double or triple antithrombotic approach with NOAC was at low risk of major bleeding, especially cerebral hemorrhage, compared with warfarin. Compared to the triple antithrombotic approach (NOAC plus dual antiplatelet), there was a similar stroke risk for patients receiving NOAC with single antiplatelet. Nonetheless, myocardial infarction and stenosis thrombus may be slightly increased in patients with NOAC plus single antiplatelet.[70] The duration of dual or triple antithrombotic approach should be based on the risk of arterial thrombosis, cardiogenic thrombosis, and bleeding.

Recommendation

• For patients undergoing elective percutaneous coronary intervention (PCI), it is recommended to stop aspirin within 1 week, continue to “double therapy” (clopidogrel + oral anticoagulant), and with single oral anticoagulant (ideally a NOAC) after 1 year. For the patients at high risk of bleeding, anticoagulant monotherapy can be considered after 6 months.

• For patients with acute coronary syndrome and PCI, triple therapy should be used for 1 month, followed by double therapy, and single anticoagulant therapy 1 year later. Standard-dose single anticoagulant is recommended for stable coronary heart disease or chronic coronary syndrome.

Elderly Patients with Comorbidities

The prevalence of multimorbidity was reported as 31.8% among the Chinese population aged over 60 years, increasing with age.[71] Multimorbidity leads to increased risks of functional decline, polypharmacy, disability, and hospitalization. Cardiovascular disease (hypertension, CAD, HF, etc.), noncardiovascular disease (diabetes, COPD, OSA, chronic kidney/liver disease, cancer, etc.), and mental disorders are common in the elderly population, which increase the risk of AF onset and AF-related complications.[72]

Lifestyle factors and comorbidities cannot be considered in isolation in relation to the progression of AF.[73] Thus, lifestyle modification may not just decrease AF risk and common comorbidities of AF in the “naïve-AF” general population, but can also effectively reduce recurrent AF in patients receiving AF ablation and its related complications. Such lifestyle and risk factor modification interventions are related to the prevention and treatment of AF and AF-related complications.[19]

Polypharmacy, with the use of more than five drugs at the same time, is common in elderly patients with AF, especially those over 75 years ([Fig. 7]). The presence of polypharmacy in AF patients is associated with adverse clinical outcomes.[74] The risk of major bleeding and nonmajor bleeding also increased significantly.[75]

Fig. 7 Multimorbidity, polypharmacy, and high-risk thromboembolism and bleeding in the elderly population with AF. F, female; M, male. (Cited from Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. J Am Heart Assoc. 2022; J Arrhythm. 2022.[8] [59])

Smart tools might help the elderly patients with AF for the cardiovascular risk and comorbidity management.[33] A web-based integrated management program improved medication adherence and quality of life, and reduced readmission in AF patients with a mean age of 73 years.[76] In the mAFA II trial, the hazard risk for the acute coronary syndrome, HF, and uncontrolled blood pressure, as the C criterion of the ABC pathway, reduced by 71%, compared to the usual care group (HR: 0.29; 95% CI: 0.19–0.45; p < 0 .001).[35]

Recommendation

The elderly population is commonly associated with multimorbidity and polypharmacy, leading to the risk of AF and AF-related complications. Lifestyle modification and appropriate measures should be taken to reduce AF progression and inappropriate use of the drugs. Smart tools might be used to facilitate risk factor and comorbidity management for the elderly patient.

Elderly Patients with Stroke

The annual prevalence of ischemic stroke is 1 to 2% among AF patients on NOAC.[77] Older patients with acute ischemic stroke have a worst prognosis, with higher bleeding risk and mortality than younger patients, but can still benefit from the thrombolysis.

AF patients with ischemic stroke or transient ischemic attack have a high risk of recurrent stroke. Infarct size, National Institutes of Health Stroke Scale (NIHSS) score, CHA₂DS₂-VASc, and HAS-BLED score should be taken into the account to decide the anticoagulant approach. For patients with NIHSS score <15 and low bleeding risk, oral anticoagulant can be initiated in 2 to 14 days. For patients with NIHSS score ≥15 and high risk of bleeding, oral anticoagulant should be restarted after 14 days. During the initial period <14 days, aspirin can be used before initiation of oral anticoagulant therapy.[78]

In addition to cardiogenic factors, ischemic stroke in patients with AF may be caused by large atherosclerotic diseases (such as symptomatic intracranial vascular stenosis). If a patient has recently undergone carotid stent implantation and the risk of bleeding is low, oral anticoagulant therapy in conjunction with antiplatelet drugs may be considered.

AF patients receiving carotid endarterectomy can receive only aspirin before and for a few days after surgery, and discontinue aspirin after resuming NOAC therapy. Patients with AF who have asymptomatic atherosclerosis and narrow internal carotid and/or intracranial arteries should be treated with statins and oral anticoagulant without additional antiplatelet therapy.

The intracranial hemorrhage (ICH) rate is about 0.23 to 0.55%/year in patients with NOAC. Based on the available evidence, the restart of NOAC can be cautiously considered 4 weeks after ICH after a multidisciplinary review, including cardiologists, stroke neurologists, etc. For the elderly patients at high risk, the potential ICH risk factors, such as cerebral amyloidosis, cerebral microbleeds, should be assessed with magnetic resonance imaging (e.g., susceptibility-weighted imaging), prior to deciding on oral anticoagulation.

Periprocedural and Perioperative Management

About 10% of patients with AF undergo invasive procedure or surgery each year. The common operation received by the elderly patients with AF were cardiovascular, gastrointestinal, and mouth. Patients aged over 75 years were more likely to receive orthopedic and ophthalmic operations.[79] The comorbidities, liver/renal dysfunction of the elderly patients, were associated with the time of stopping and restarting anticoagulants during peri-operation. The perioperative anticoagulation strategy in elderly patients with AF should consider the patient's factors, the type of the operation (interventions with minor bleeding risk, low bleeding risk, or high bleeding risk),[80] and the anticoagulant drugs ([Fig. 8]).

Fig. 8 Periprocedural and perioperative risk assessment of the elderly population with AF. Intervention with minor bleeding: e.g., dental extractions (1–3 teeth), paradontal surgery, implant positioning, subgingival scalling/cleaning; cataract or glaucoma intervention endoscopy without biopsy or resection; superficial surgery (e.g., abscess incision, small dermatologic excisions, skin biopsy); pacemaker or ICD implantation (except complex procedures); electrophysiological study or catheter ablation (except complex procedures); routine elective coronary/peripheral artery intervention (except complex procedures); intramuscular injection (e.g., vaccination). Intervention with low-risk bleeding: e.g., complex dental procedures; endoscopy with simple biopsy; small orthopedic surgery (foot, hand, arthroscopy. Intervention with high-risk interventions: e.g., cardiac surgery; peripheral arterial revascularization surgery (e.g., aortic aneurysm repair, vascular bypass); complex invasive cardiological interventions, including lead extraction, (epicardial) VT ablation, chronic total occlusion, PCI, etc. Neurosurgery spinal or epidural anesthesia; lumbar diagnostic puncture; complex endoscopy (e.g., multiple/large polypectomy, ERCP with sphincterotomy, etc.); abdominal surgery (including liver biopsy); thoracic surgery; major urologic surgery/biopsy (including kidney); extracorporeal shockwave lithotripsy; major orthopedic surgery. (Cited from 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021.[80])

Warfarin is usually stopped at least 5 days prior to the procedures with low/high bleeding risk with the obvious clinical impact. The elderly patients with comorbidities, patients with very low-dose warfarin requirements, and those with a higher target INR range, a longer period of warfarin interruption may be needed.

NOACs can be stopped close to the procedure usually without bridging. There was no significant impact of continuing NOAC on the thromboembolic or bleeding rates, compared to a bridging approach.[81] [82] Also, if NOACs are interrupted for >72 hours, the likelihood of any residual NOAC level appears very low.[83] [84]

The continuation, discontinuation, bridging, and resumption of anticoagulation, with regard to the time points in the perioperative period, are illustrated in [Figs. 9] and [10].

Fig. 9 Continuation, discontinuation, bridging, or resumption of anticoagulation with warfarin, with regard to the time points in the perioperative period. INR, international normalized ratio; LMWH, low-molecular-weight heparin; OAC, oral anticoagulant.

Fig. 10 Continuation, discontinuation, bridging, or resumption of anticoagulation with NOACs, with regard to the time points in the perioperative period. NOAC, non-vitamin K antagonist oral anticoagulant.

Recommendation

• Warfarin is stopped at least 5 days prior to the intervention with low/high bleeding risk, depending on the INR range, and restart with the bridging of low-molecular-weight heparin ([Fig. 9]).

• NOACs should be stopped at least 24 hours and up to 96 hours depending on the bleeding risk and the urgency of surgery/operation ([Fig. 10]).

Elderly Patients with Cancer

Both AF and tumors increase the risk of thrombosis. Gastrointestinal or hematological tumors also raise the risk of bleeding. Warfarin, low-molecular-weight heparin, or NOAC can be considered when the CHA₂DS₂-VASc score is ≥2 and platelet count is >50 × 10⁹/L. Careful and regular monitoring is advised.

Frailty

Both AF and frailty increase with aging. The reported rate of the frailty ranges from 4.4 to 75.4%.[85] AF contributes to the risk of frailty, while frailty results in poor adherence to anticoagulant.

Recommendation

NOACs are recommended for the elderly patients with AF and frailty.

The management of chronic conditions in the elderly population with AF is summarized in [Fig. 11].

Fig. 11 Management of chronic conditions in the elderly population with AF. ACE inhibitors, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; ARBs, angiotensin receptor blockers; NOACs, non-vitamin K oral antagonist anticoagulants.

Conflict of Interest

G.Y.H.L. is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-PI of the AFFIRMO project on multimorbidity in AF (grant agreement No 899871), TARGET project on digital twins for personalised management of atrial fibrillation and stroke (grant agreement No 101136244) and ARISTOTELES project on artificial intelligence for management of chronic long term conditions (grant agreement No 101080189), which are all funded by the EU's Horizon Europe Research & Innovation programme. There is no competing interest from any other author.

Note

This is an executive summary of the full consensus guideline, which is published in Chinese Journal of Cardiac Arrhythmias (Chin J Cardiac Arrhythm 2024; DOI: 10.3760/cma.j.cnl 13859-20240130-00012).

^* The expert reviewers details are mentioned in the Supplementary Appendix (available in the online version)

The review process for this paper was fully handled by Christian Weber, Editor in Chief.

• References

• 1 Li X, Ding W, Hua Y, Wang Y, Qin M, Fan J. Expert consensus on the management of atrial fibrillation in elderly population (2011), endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group). Chin J Geriatric 2011; 30: 894-908
• 2 Qing M, Zhang X, Zhang Y, Guo Y, Li X. Expert consensus on the management of atrial fibrillation in elderly population (2016), endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine. Chin J Geriatric 2016; 35: 14-27
• 3 Wang Y, Guo Y, Qin M, Fan J, Tang M, Wang H, Li X. 2024 Chinese expert consensus guidelines on the diagnosis and treatment of Atrial Fibrillation in the Elderly, endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular branch). Chin J Cardiac Arrhythm 2024. Doi: 103760/cmajcnl 13859–20240130–00012
• 4 Zhang J, Johnsen SP, Guo Y, Lip GYH. Epidemiology of atrial fibrillation: geographic/ecological risk factors, age, sex, genetics. Card Electrophysiol Clin 2021; 13 (01) 1-23
• 5 Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GYH. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest 2015; 147 (01) 109-119
• 6 Shi S, Tang Y, Zhao Q. et al; China Atrial Fibrillation Center Project Team). Prevalence and risk of atrial fibrillation in China: a national cross-sectional epidemiological study. Lancet Reg Health West Pac 2022; 23: 100439
• 7 Chinese Medical Doctor Association. Blue Book on the prevention and treatment of atrial fibrillation in China 2018: People's Medical Publishing House in China, People's Health Electronic Audio and Video Publishing House in China. 2019
• 8 Kotalczyk A, Guo Y, Stefil M, Wang Y, Lip GYH. ChiOTEAF Registry Investigators. Effects of the Atrial Fibrillation Better Care Pathway on outcomes among clinically complex Chinese patients with atrial fibrillation with multimorbidity and polypharmacy: a report from the ChiOTEAF registry. J Am Heart Assoc 2022; 11 (07) e024319
• 9 Romiti GF, Proietti M, Bonini N. et al; GLORIA-AF Investigators. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost 2022; 122 (12) 2030-2041
• 10 Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2024; 124 (02) 135-148
• 11 Zheng Y, Li S, Liu X, Lip GYH, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thromb Haemost 2023; (e-pub ahead of print) DOI: 10.1055/s-0043-1770724.
• 12 Guo Y, Kotalczyk A, Imberti JF, Wang Y, Lip GYH. ChiOTEAF Registry Investigators. Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. Eur Heart J Qual Care Clin Outcomes 2023; 9 (02) 169-176
• 13 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022; 122 (10) 1625-1652
• 14 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian Paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
• 15 Kang DS, Yang PS, Kim D. et al. Racial differences in ischemic and hemorrhagic stroke: an ecological epidemiological study. Thromb Haemost 2024; (e-pub ahead of print) DOI: 10.1055/a-2278-8769.
• 16 Kang DS, Yang PS, Kim D. et al. Racial differences in bleeding risk: an ecological epidemiological study comparing Korea and United Kingdom subjects. Thromb Haemost 2024; (e-pub ahead of print) DOI: 10.1055/a-2269-1123.
• 17 Kwon S, Lee SR, Choi EK. et al. Impact of unhealthy lifestyles on patients with atrial fibrillation at low risk of stroke: a nationwide cohort study. Am J Med 2024; 137 (01) 37-46.e6
• 18 Joglar JA, Chung MK, Armbruster AL. et al; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2024; 149 (01) e1-e156
• 19 Chung MK, Eckhardt LL, Chen LY. et al; American Heart Association Electrocardiography and Arrhythmias Committee and Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Lifestyle and Cardiometabolic Health. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. Circulation 2020; 141 (16) e750-e772
• 20 Nagashima K, Okumura Y, Yokoyama K. et al; REAL AF StudyInvestigators. Comparison of continuous 24-h and 14-day monitoring for detection of otherwise unknown atrial fibrillation: a registry to identify Japanese concealed atrial fibrillation (REAL-AF)-based study. Heart Vessels 2020; 35 (05) 689-698
• 21 Guo Y, Wang H, Zhang H. et al; MAFA II Investigators. Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol 2019; 74 (19) 2365-2375
• 22 Chen Y, Wang W, Guo Y, Zhang H, Chen Y, Xie L. A single-center validation of the accuracy of a photoplethysmography-based smartwatch for screening obstructive sleep apnea. Nat Sci Sleep 2021; 13: 1533-1544
• 23 Lubitz SA, Faranesh AZ, Selvaggi C. et al. Detection of atrial fibrillation in a large population using wearable devices: the Fitbit Heart Study. Circulation 2022; 146 (19) 1415-1424
• 24 Guo Y, Zhang H, Lip GYH. mAF-App II Trial investigators. Consumer-led screening for atrial fibrillation: a report from the mAFA-II trial long-term extension cohort. JACC Asia 2022; 2 (06) 737-746
• 25 Babar F, Cheema AM, Ahmad Z. et al. Sensitivity and specificity of wearables for atrial fibrillation in elderly populations: a systematic review. Curr Cardiol Rep 2023; 25 (07) 761-779
• 26 Pandey AK, Xu K, Zhang L. et al. Lower versus standard INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Thromb Haemost 2020; 120 (03) 484-494
• 27 Vitolo M, Imberti JF, Maisano A. et al. Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis. Eur J Intern Med 2021; 92: 100-106
• 28 Kirchhof P, Toennis T, Goette A. et al; NOAH-AFNET 6 Investigators. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med 2023; 389 (13) 1167-1179
• 29 Becher N, Toennis T, Bertaglia E. et al. Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h. Eur Heart J 2024; 45 (10) 837-849
• 30 Imberti JF, Bonini N, Tosetti A. et al. Atrial high-rate episodes detected by cardiac implantable electronic devices: dynamic changes in episodes and predictors of incident atrial fibrillation. Biology (Basel) 2022; 11 (03) 11
• 31 Healey JS, Lopes RD, Granger CB. et al; ARTESIA Investigators. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 2024; 390 (02) 107-117
• 32 McIntyre WF, Benz AP, Becher N. et al. Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. Circulation 2024; 149 (13) 981-988
• 33 Linz D, Gawalko M, Betz K. et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur 2024; 37: 100786
• 34 Guo Y, Romiti GF, Proietti M, Bonini N, Zhang H, Lip GYH. mAF-App II Trial Investigators. Mobile health technology integrated care in older atrial fibrillation patients: a subgroup analysis of the mAFA-II randomised clinical trial. Age Ageing 2022; 51 (11) 51
• 35 Yao Y, Guo Y, Lip GYH. mAF-App II Trial investigators. The effects of implementing a mobile health-technology supported pathway on atrial fibrillation-related adverse events among patients with multimorbidity: the mAFA-II randomized clinical trial. JAMA Netw Open 2021; 4 (12) e2140071
• 36 Guo Y, Corica B, Romiti GF, Proietti M, Zhang H, Lip GYH. mAF-App II Trial Investigators. Mobile health technology integrated care in atrial fibrillation patients with diabetes mellitus in China: a subgroup analysis of the mAFA-II cluster randomized clinical trial. Eur J Clin Invest 2023; 53 (09) e14031
• 37 Guo Y, Romiti GF, Corica B. et al. Mobile health-technology integrated care in atrial fibrillation patients with heart failure: a report from the mAFA-II randomized clinical trial. Eur J Intern Med 2023; 107: 46-51
• 38 Guo Y, Romiti GF, Sagris D. et al; mAF-App II trial investigators. Mobile health-technology integrated care in secondary prevention atrial fibrillation patients: a post-hoc analysis from the mAFA-II randomized clinical trial. Intern Emerg Med 2023; 18 (04) 1041-1048
• 39 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the 'Atrial Fibrillation Better Care' pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
• 40 Luo X, Xu W, Ming WK. et al. Cost-effectiveness of mobile health-based integrated care for atrial fibrillation: model development and data analysis. J Med Internet Res 2022; 24 (04) e29408
• 41 Camacho EM, Lip GYH. Estimating the impact of implementing an integrated care management approach with Atrial fibrillation Better Care (ABC) pathway for patients with atrial fibrillation in England from 2020-2040. Eur Heart J Qual Care Clin Outcomes 2023; (e-pub ahead of print) DOI: 10.1093/ehjqcco/qcad055.
• 42 Serna MJ, Rivera-Caravaca JM, López-Gálvez R. et al. Dynamic assessment of CHA₂DS₂-VASc and HAS-BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients. Rev Esp Cardiol (Engl Ed) 2024; (e-pub ahead of print) DOI: 10.1016/j.rec.2024.02.011.
• 43 Chao TF, Liao JN, Tuan TC. et al. Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (Males) or 1 (females): implications for reassessment of stroke risk in initially 'low-risk' patients. Thromb Haemost 2019; 119 (07) 1162-1170
• 44 Guo Y, Zhu H, Chen Y, Lip GYH. Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. Am J Med 2018; 131 (02) 185-192
• 45 Chao TF, Lip GYH, Lin YJ. et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost 2018; 118 (04) 768-777
• 46 Proietti M, Romiti GF, Vitolo M, Potpara TS, Boriani G, Lip GYH. Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry. Eur Heart J Qual Care Clin Outcomes 2022; 8 (07) 778-786
• 47 Borre ED, Goode A, Raitz G. et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018; 118 (12) 2171-2187
• 48 Guo Y, Lane DA, Chen Y, Lip GYH. mAF-App II Trial investigators. Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial. Am J Med 2020; 133 (10) 1195-1202.e2
• 49 Fong JH, Youn Y. Assessing patterns and stability of ADL hierarchical scales for functional disability assessment. Gerontologist 2023; 63 (04) 773-782
• 50 Egashira R, Sato T, Miyake A. et al. The Japan Frailty Scale is a promising screening test for frailty and pre-frailty in Japanese elderly people. Gene 2022; 844: 146775
• 51 Long J, Cai T, Huang X, Zhou Y, Kuang J, Wu L. Reference value for the TUGT in healthy older people: a systematic review and meta-analysis. Geriatr Nurs 2020; 41 (03) 325-330
• 52 Jia X, Wang Z, Huang F. et al. A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study. BMC Psychiatry 2021; 21 (01) 485
• 53 Shurrab M, Jackevicius CA, Austin PC. et al. Association between concurrent use of amiodarone and DOACs and risk of bleeding in patients with atrial fibrillation. Am J Cardiol 2023; 186: 58-65
• 54 Ray WA, Chung CP, Stein CM. et al. Risk for bleeding-related hospitalizations during use of amiodarone with apixaban or rivaroxaban in patients with atrial fibrillation : a retrospective cohort study. Ann Intern Med 2023; 176 (06) 769-778
• 55 Gowda RM, Khan IA, Punukollu G. et al. Use of ibutilide for cardioversion of recent-onset atrial fibrillation and flutter in elderly. Am J Ther 2004; 11 (02) 95-97
• 56 Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2019; 9 (09) CD005049
• 57 Kirchhof P, Camm AJ, Goette A. et al; EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020; 383 (14) 1305-1316
• 58 Rillig A, Borof K, Breithardt G. et al. Early rhythm control in patients with atrial fibrillation and high comorbidity burden. Circulation 2022; 146 (11) 836-847
• 59 Guo Y, Wang H, Kotalczyk A, Wang Y, Lip GYH. ChiOTEAF Registry Investigators. One-year follow-up results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. J Arrhythm 2021; 37 (05) 1227-1239
• 60 Guo Y, Kotalczyk A, Imberti JF, Wang Y, Lip GY. ChiOTEAF Registry Investigators. Oral anticoagulation improves survival in very elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. Int J Stroke 2022; 17 (06) 661-668
• 61 Kotalczyk A, Guo Y, Wang Y, Lip GY. ChiOTEAF Registry Investigators. Are low doses of non-vitamin K antagonists effective in Chinese patients with atrial fibrillation? A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. Int J Stroke 2021; (e-pub ahead of print) DOI: 10.1177/17474930211053140.
• 62 Silverio A, Di Maio M, Prota C. et al. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients. Eur Heart J Cardiovasc Pharmacother 2021; 7 (FI1): f20-f29
• 63 Chao TF, Chiang CE, Chan YH. et al. Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation. Heart Rhythm 2021; 18 (06) 871-877
• 64 Chan YH, Chao TF, Chen SW. et al. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 2023; 9 (08) 681-691
• 65 Guo Y, Imberti JF, Kotalczyk A, Wang Y, Lip GYH. ChiOTEAF Registry Investigators. Atrial fibrillation better care pathway adherent care improves outcomes in Chinese patients with atrial fibrillation. JACC Asia 2022; 2 (04) 422-429
• 66 Gibson CM, Mehran R, Bode C. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375 (25) 2423-2434
• 67 Cannon CP, Bhatt DL, Oldgren J. et al; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377 (16) 1513-1524
• 68 Lopes RD, Heizer G, Aronson R. et al; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380 (16) 1509-1524
• 69 Vranckx P, Valgimigli M, Eckardt L. et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019; 394 (10206): 1335-1343
• 70 Galli M, Andreotti F, D'Amario D, Porto I, Crea F. Stent thrombosis with dual antithrombotic therapy in atrial fibrillation-ACS/PCI trials. J Am Coll Cardiol 2020; 75 (14) 1727-1728
• 71 Fan J, Sun Z, Yu C. et al; China Kadoorie Biobank Collaborative Group. Multimorbidity patterns and association with mortality in 0.5 million Chinese adults. Chin Med J (Engl) 2022; 135 (06) 648-657
• 72 Ogawa H, An Y, Nishi H. et al; Fushimi AF Registry Investigators. Characteristics and clinical outcomes in atrial fibrillation patients classified using cluster analysis: the Fushimi AF Registry. Europace 2021; 23 (09) 1369-1379
• 73 Shantsila E, Choi EK, Lane DA, Joung B, Lip GYH. Atrial fibrillation: comorbidities, lifestyle, and patient factors. Lancet Reg Health Eur 2024; 37: 100784
• 74 Chen N, Alam AB, Lutsey PL. et al. Polypharmacy, adverse outcomes, and treatment effectiveness in patients ≥75 with atrial fibrillation. J Am Heart Assoc 2020; 9 (11) e015089
• 75 Proietti M, Raparelli V, Olshansky B, Lip GY. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol 2016; 105 (05) 412-420
• 76 Hsieh HL, Kao CW, Cheng SM, Chang YC. A web-based integrated management program for improving medication adherence and quality of life, and reducing readmission in patients with atrial fibrillation: randomized controlled trial. J Med Internet Res 2021; 23 (09) e30107
• 77 Macha K, Marsch A, Siedler G. et al. Cerebral ischemia in patients on direct oral anticoagulants. Stroke 2019; 50 (04) 873-879
• 78 Klijn CJ, Paciaroni M, Berge E. et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline. Eur Stroke J 2019; 4 (03) 198-223
• 79 Unverdorben M, von Heymann C, Santamaria A. et al. Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study. BMC Cardiovasc Disord 2020; 20 (01) 504
• 80 Steffel J, Collins R, Antz M. et al; External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021; 23 (10) 1612-1676
• 81 Sherwood MW, Douketis JD, Patel MR. et al; ROCKET AF Investigators. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014; 129 (18) 1850-1859
• 82 Douketis JD, Healey JS, Brueckmann M. et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost 2015; 113 (03) 625-632
• 83 Godier A, Dincq AS, Martin AC. et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J 2017; 38 (31) 2431-2439
• 84 Shaw JR, Li N, Vanassche T. et al. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Adv 2020; 4 (15) 3520-3527
• 85 Villani ER, Tummolo AM, Palmer K. et al. Frailty and atrial fibrillation: A systematic review. Eur J Intern Med 2018; 56: 33-38

Publikationsverlauf

Eingereicht: 04. April 2024

Angenommen: 04. Mai 2024

Accepted Manuscript online:
14. Mai 2024

Artikel online veröffentlicht:
02. Juli 2024